…The intervention scheme under CBN is to support healthcare sector
The Secretary to the Government of the Federation (SGF) on Monday inaugurated Body of Experts (BOE) of the Central Bank of Nigeria Healthcare Sector Research and Development Intervention Scheme (HSRDIS).
This was disclosed in a public statement issued out on the official Twitter handle by the CBN Governor, Godwin Emefiele.
According to the statement, the HSRDIS is established to address the difficulties challenging research and development investment in the healthcare sector.
Prof. Mojisola Adeyeye who is the Director-General of National Agency for Food and Drug Administration and Control (NAFDAC) oversees the BOE.
“Director-General, National Agency for Food and Drug Administration and Control (NAFDAC), Prof. Mojisola Adeyeye heads Body of Experts (BOE) to review and evaluate submitted research proposals and provide recommendations for financing the identified R&D proposals,” Emefiele said in the statement.
Read also: BREAKING! CBN waives guarantor requirements for households, SMEs applying for N50bn COVID-19 facility
Emefiele revealed that projects that are worth N26.278 billion have been sponsored under the N100 billion credit support intervention for the healthcare industry.
He further stated that the scheme will help to speed up the country’s research and development towards locally-made medications.
“CBN HSRDIS is designed to increase Nigeria’s research and development activities to support the development of validated Nigerian made vaccines, drugs and herbal medicines.
CBN to provide grants to biotechnological and pharmaceutical companies, institutions, researchers, and research institutes, to boost domestic capacity to curb the spread of COVID-19 and other communicable and non-communicable diseases.
CBN HSRDIS to support capacity of relevant health agencies towards attaining WHO Maturtiy Level 3 prerequisite for manufacturing of vaccines in Nigeria,” he said.
Research institutes and industries will also partner to control, prevent and treat diseases peculiar to the country as well as reducing reliance on foreign medications.